Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AstraZeneca and Alexion today announced that they have entered into a definitive agreement under which AstraZeneca will acquire Alexion for $175 per share,…
AstraZeneca has entered into a definitive agreement to acquire Alexion Pharmaceuticals, a leader in rare diseases and complement biology, for approximately…
AstraZeneca FY2024 results (6 Feb 2025): Total Revenue from Rare Disease medicines $7,764m, 16-17% of overall Total Revenue; Ultomiris FY2024 revenue…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca acquired Alexion Pharmaceuticals for approximately $39 billion, establishing a new rare disease franchise anchored by complement inhibitors Soliris and Ultomiris, accelerating AstraZeneca's strategic and financial development toward its $40 billion revenue target.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. (this deal) | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2020 deals · AstraZeneca PLC deals · Hematology deals